Table 2.

Effects of pre‐treatments with individual PBPs 1–5, PBP‐mix and EGCG on latency period, multiplicity and incidence of DMBA‐initiated and TPA‐promoted mouse skin carcinogenesis

Group No. (as per Table 1a)	Treatment	Latency (in weeks)	Multiplicity Time points (in weeks)				Incidence (%) Time points (in weeks)
			10	20	30	40	10	20	30	40
2	Acetone + TPA	11 ± 0.28	0.41 ± 0.001	4.00 ± 0.01	8.24 ± 0.09	12.00 ± 0.1	13	100	100	100
10	PBP1 + TPA	17 ± 1.72	0.05 ± 0.002*	0.91 ± 0.05*	1.90 ± 0.01	4.20 ± 0.04*	6	58*	76	100
11	PBP2 + TPA	14 ± 1.58*	0.00*	0.35 ± 0.001*	1.00 ± 0.05*	2.90 ± 0.05	0	31*	63*	69*
12	PBP3 + TPA	18 ± 1.01*	0.00*	0.59 ± 0.002*	2.50 ± 0.04*	4.21 ± 0.04*	0	38*	100	100
13	PBP4 + TPA	15 ± 1.44*	0.05 ± 0.001	1.42 ± 0.01	3.90 ± 0.04*	5.59 ± 0.04*	6	70	100	100
14	PBP5 + TPA	11 ± 1.21	0.39 ± 0.003	2.00 ± 0.05	4.10 ± 0.05*	7.01 ± 0.1	13	95	100	100
15	PBPmix + TPA	20 ± 1.58*	0.00*	0.81 ± 0.02	3.20 ± 0.02*	4.90 ± 0.09	0	100	100	100
16	EGCG + TPA	19 ± 1.92	0.00*	1.19 ± 0.004*	3.80 ± 0.02	5.20 ± 0.09	0	72	100	100

Mean ± SE; n = 10 mice per group.

^* P < 0.01 compared to group no. 2 – acetone + TPA‐treated, anova with Tukey's test for latency and multiplicity and Fisher's exact test for incidence.